KRT19 and skin disorder: Only the IgM antibody against cytokeratin 19 showed an increase from baseline to the time of toxicity among dermatitis cases (p=0.014, FDR=0.93) and was elevated during dermatitis events compared with the 12-week control samples (p=0.016, FDR=0.85) (Figure 4).